LEO Pharma Connects Affiliates with Veeva Vault Safety
Veeva Systems has announced that LEO Pharma is using Veeva Vault Safety to optimize its safety operations. With this foundation, the company can incorporate affiliates into safety workflows, boost operational efficiencies, ensure compliance, and unify its global pharmacovigilance data on one platform.
“LEO Pharma is deeply committed to the safety of patients using its products,” said Pilar Carrero, vice president of global safety at LEO Pharma in a press release. “With Veeva Vault Safety, we now have real-time visibility into adverse events and data transparency for affiliates that helps us work even better together.”
Vault Safety is helping LEO Pharma improve oversight of case intake, processing, submission, and distribution while simplifying safety workflows and eliminating data reconciliation with affiliates and partners. By standardizing drug development on Veeva Development Cloud, LEO Pharma can better connect safety to other crucial business areas like clinical, regulatory, and quality.
“Now, all parties have visibility into case data, ownership, and status, facilitating improved collaboration and sharing of learnings,” said John Lawrie, vice president of Vault Safety at Veeva in a press release. “Veeva is happy to partner with LEO Pharma to make its safety operations simpler and more effective.”
Vault Safety is a safety case management system that enables adverse event intake, processing, and submission for clinical and marketed products. It is part of Veeva Development Cloud.
Reference
LEO Pharma Connects Affiliates with Veeva Vault Safety to Transform Safety Operations. (2023, October 3). Veeva.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Obe-Cel Achieves High Response Rates, Durable Outcomes in r/r B-Cell Acute Lymphoblastic Leukemia
December 3rd 2024CAR T-cell therapy obecabtagene autoleucel produced high response rates, durable outcomes, and low toxicity in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia, especially benefiting those with low-to-intermediate bone marrow burden.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Opdivo plus Yervoy Significantly Outperforms Chemotherapy in MSI-H/dMMR Metastatic Colorectal Cancer
December 2nd 2024Phase III CheckMate 8HW trial results demonstrated that the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) significantly improves progression-free survival and has a better safety profile compared to chemotherapy in the first-line treatment of MSI-H or dMMR metastatic colorectal cancer.
